Pharma & Healthcare
Global Anti-Parkinson's Disease Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
- Oct 21, 25
- ID: 556486
- Pages: 212
- Figures: 202
- Views: 6
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Anti-Parkinson's Disease Drugs market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Guangzhou Kanghe Pharmaceutical Co., Ltd.
Tianjin Lisheng Pharmaceutical Co., Ltd.
Changzhou Kangpu Pharmaceutical Co., Ltd.
Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd.
Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd.
Hunan Zhongnan Pharmaceutical Co., Ltd.
Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
Ningbo Dahongying Pharmaceutical Co., Ltd.
Beijing Fuyuan Pharmaceutical Co., Ltd.
Zhejiang Huahai Pharmaceutical Co., Ltd.
Hangzhou Guoguang Pharmaceutical Co., Ltd.
Merck
Akorn
GSK
Novartis
Boehringer Ingelheim
Teva Pharmaceutical
Abbvie
Kyowa Kirin
Astellas Pharma
Desitin Arzneimittel
Endo International plc
Roche Holding AG
Lundbeck
Valeant
Apokyn
Orion
Stada Arzneimittel
Bausch Health
Segment by Type
Anticholinergics
Dopaminergics
Segment by Application
Hospital
Clinic
Pharmacy
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Anti-Parkinson's Disease Drugs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Anti-Parkinson's Disease Drugs market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Guangzhou Kanghe Pharmaceutical Co., Ltd.
Tianjin Lisheng Pharmaceutical Co., Ltd.
Changzhou Kangpu Pharmaceutical Co., Ltd.
Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd.
Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd.
Hunan Zhongnan Pharmaceutical Co., Ltd.
Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
Ningbo Dahongying Pharmaceutical Co., Ltd.
Beijing Fuyuan Pharmaceutical Co., Ltd.
Zhejiang Huahai Pharmaceutical Co., Ltd.
Hangzhou Guoguang Pharmaceutical Co., Ltd.
Merck
Akorn
GSK
Novartis
Boehringer Ingelheim
Teva Pharmaceutical
Abbvie
Kyowa Kirin
Astellas Pharma
Desitin Arzneimittel
Endo International plc
Roche Holding AG
Lundbeck
Valeant
Apokyn
Orion
Stada Arzneimittel
Bausch Health
Segment by Type
Anticholinergics
Dopaminergics
Segment by Application
Hospital
Clinic
Pharmacy
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Anti-Parkinson's Disease Drugs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Anti-Parkinson's Disease Drugs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Anti-Parkinson's Disease Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Anticholinergics
1.2.3 Dopaminergics
1.3 Market Segmentation by Application
1.3.1 Global Anti-Parkinson's Disease Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Pharmacy
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Anti-Parkinson's Disease Drugs Revenue Estimates and Forecasts 2020-2031
2.2 Global Anti-Parkinson's Disease Drugs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Anti-Parkinson's Disease Drugs Sales Estimates and Forecasts 2020-2031
2.4 Global Anti-Parkinson's Disease Drugs Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Anti-Parkinson's Disease Drugs Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Anti-Parkinson's Disease Drugs Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Anticholinergics Market Size by Manufacturers
3.5.2 Dopaminergics Market Size by Manufacturers
3.6 Global Anti-Parkinson's Disease Drugs Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Anti-Parkinson's Disease Drugs Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Anti-Parkinson's Disease Drugs Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Anti-Parkinson's Disease Drugs Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Anti-Parkinson's Disease Drugs Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Anti-Parkinson's Disease Drugs Sales and Revenue by Type (2020-2031)
6.4 North America Anti-Parkinson's Disease Drugs Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Anti-Parkinson's Disease Drugs Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Anti-Parkinson's Disease Drugs Sales and Revenue by Type (2020-2031)
7.4 Europe Anti-Parkinson's Disease Drugs Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Anti-Parkinson's Disease Drugs Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Anti-Parkinson's Disease Drugs Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Anti-Parkinson's Disease Drugs Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Anti-Parkinson's Disease Drugs Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Anti-Parkinson's Disease Drugs Sales and Revenue by Type (2020-2031)
9.4 Central and South America Anti-Parkinson's Disease Drugs Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Anti-Parkinson's Disease Drugs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Anti-Parkinson's Disease Drugs Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Anti-Parkinson's Disease Drugs Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Anti-Parkinson's Disease Drugs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Guangzhou Kanghe Pharmaceutical Co., Ltd.
11.1.1 Guangzhou Kanghe Pharmaceutical Co., Ltd. Corporation Information
11.1.2 Guangzhou Kanghe Pharmaceutical Co., Ltd. Business Overview
11.1.3 Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.1.4 Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Product in 2024
11.1.6 Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Application in 2024
11.1.7 Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Geographic Area in 2024
11.1.8 Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs SWOT Analysis
11.1.9 Guangzhou Kanghe Pharmaceutical Co., Ltd. Recent Developments
11.2 Tianjin Lisheng Pharmaceutical Co., Ltd.
11.2.1 Tianjin Lisheng Pharmaceutical Co., Ltd. Corporation Information
11.2.2 Tianjin Lisheng Pharmaceutical Co., Ltd. Business Overview
11.2.3 Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.2.4 Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Product in 2024
11.2.6 Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Application in 2024
11.2.7 Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Geographic Area in 2024
11.2.8 Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs SWOT Analysis
11.2.9 Tianjin Lisheng Pharmaceutical Co., Ltd. Recent Developments
11.3 Changzhou Kangpu Pharmaceutical Co., Ltd.
11.3.1 Changzhou Kangpu Pharmaceutical Co., Ltd. Corporation Information
11.3.2 Changzhou Kangpu Pharmaceutical Co., Ltd. Business Overview
11.3.3 Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.3.4 Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Product in 2024
11.3.6 Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Application in 2024
11.3.7 Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Geographic Area in 2024
11.3.8 Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs SWOT Analysis
11.3.9 Changzhou Kangpu Pharmaceutical Co., Ltd. Recent Developments
11.4 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd.
11.4.1 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Corporation Information
11.4.2 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Business Overview
11.4.3 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.4.4 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Product in 2024
11.4.6 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Application in 2024
11.4.7 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Geographic Area in 2024
11.4.8 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs SWOT Analysis
11.4.9 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Recent Developments
11.5 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd.
11.5.1 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Corporation Information
11.5.2 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Business Overview
11.5.3 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.5.4 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Product in 2024
11.5.6 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Application in 2024
11.5.7 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Geographic Area in 2024
11.5.8 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs SWOT Analysis
11.5.9 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Recent Developments
11.6 Hunan Zhongnan Pharmaceutical Co., Ltd.
11.6.1 Hunan Zhongnan Pharmaceutical Co., Ltd. Corporation Information
11.6.2 Hunan Zhongnan Pharmaceutical Co., Ltd. Business Overview
11.6.3 Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.6.4 Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Hunan Zhongnan Pharmaceutical Co., Ltd. Recent Developments
11.7 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
11.7.1 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Corporation Information
11.7.2 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Business Overview
11.7.3 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.7.4 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Recent Developments
11.8 Ningbo Dahongying Pharmaceutical Co., Ltd.
11.8.1 Ningbo Dahongying Pharmaceutical Co., Ltd. Corporation Information
11.8.2 Ningbo Dahongying Pharmaceutical Co., Ltd. Business Overview
11.8.3 Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.8.4 Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Ningbo Dahongying Pharmaceutical Co., Ltd. Recent Developments
11.9 Beijing Fuyuan Pharmaceutical Co., Ltd.
11.9.1 Beijing Fuyuan Pharmaceutical Co., Ltd. Corporation Information
11.9.2 Beijing Fuyuan Pharmaceutical Co., Ltd. Business Overview
11.9.3 Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.9.4 Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Beijing Fuyuan Pharmaceutical Co., Ltd. Recent Developments
11.10 Zhejiang Huahai Pharmaceutical Co., Ltd.
11.10.1 Zhejiang Huahai Pharmaceutical Co., Ltd. Corporation Information
11.10.2 Zhejiang Huahai Pharmaceutical Co., Ltd. Business Overview
11.10.3 Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.10.4 Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Developments
11.11 Hangzhou Guoguang Pharmaceutical Co., Ltd.
11.11.1 Hangzhou Guoguang Pharmaceutical Co., Ltd. Corporation Information
11.11.2 Hangzhou Guoguang Pharmaceutical Co., Ltd. Business Overview
11.11.3 Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.11.4 Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Hangzhou Guoguang Pharmaceutical Co., Ltd. Recent Developments
11.12 Merck
11.12.1 Merck Corporation Information
11.12.2 Merck Business Overview
11.12.3 Merck Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.12.4 Merck Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Merck Recent Developments
11.13 Akorn
11.13.1 Akorn Corporation Information
11.13.2 Akorn Business Overview
11.13.3 Akorn Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.13.4 Akorn Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.5 Akorn Recent Developments
11.14 GSK
11.14.1 GSK Corporation Information
11.14.2 GSK Business Overview
11.14.3 GSK Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.14.4 GSK Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.14.5 GSK Recent Developments
11.15 Novartis
11.15.1 Novartis Corporation Information
11.15.2 Novartis Business Overview
11.15.3 Novartis Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.15.4 Novartis Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.15.5 Novartis Recent Developments
11.16 Boehringer Ingelheim
11.16.1 Boehringer Ingelheim Corporation Information
11.16.2 Boehringer Ingelheim Business Overview
11.16.3 Boehringer Ingelheim Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.16.4 Boehringer Ingelheim Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.16.5 Boehringer Ingelheim Recent Developments
11.17 Teva Pharmaceutical
11.17.1 Teva Pharmaceutical Corporation Information
11.17.2 Teva Pharmaceutical Business Overview
11.17.3 Teva Pharmaceutical Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.17.4 Teva Pharmaceutical Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.17.5 Teva Pharmaceutical Recent Developments
11.18 Abbvie
11.18.1 Abbvie Corporation Information
11.18.2 Abbvie Business Overview
11.18.3 Abbvie Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.18.4 Abbvie Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.18.5 Abbvie Recent Developments
11.19 Kyowa Kirin
11.19.1 Kyowa Kirin Corporation Information
11.19.2 Kyowa Kirin Business Overview
11.19.3 Kyowa Kirin Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.19.4 Kyowa Kirin Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.19.5 Kyowa Kirin Recent Developments
11.20 Astellas Pharma
11.20.1 Astellas Pharma Corporation Information
11.20.2 Astellas Pharma Business Overview
11.20.3 Astellas Pharma Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.20.4 Astellas Pharma Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.20.5 Astellas Pharma Recent Developments
11.21 Desitin Arzneimittel
11.21.1 Desitin Arzneimittel Corporation Information
11.21.2 Desitin Arzneimittel Business Overview
11.21.3 Desitin Arzneimittel Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.21.4 Desitin Arzneimittel Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.21.5 Desitin Arzneimittel Recent Developments
11.22 Endo International plc
11.22.1 Endo International plc Corporation Information
11.22.2 Endo International plc Business Overview
11.22.3 Endo International plc Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.22.4 Endo International plc Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.22.5 Endo International plc Recent Developments
11.23 Roche Holding AG
11.23.1 Roche Holding AG Corporation Information
11.23.2 Roche Holding AG Business Overview
11.23.3 Roche Holding AG Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.23.4 Roche Holding AG Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.23.5 Roche Holding AG Recent Developments
11.24 Lundbeck
11.24.1 Lundbeck Corporation Information
11.24.2 Lundbeck Business Overview
11.24.3 Lundbeck Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.24.4 Lundbeck Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.24.5 Lundbeck Recent Developments
11.25 Valeant
11.25.1 Valeant Corporation Information
11.25.2 Valeant Business Overview
11.25.3 Valeant Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.25.4 Valeant Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.25.5 Valeant Recent Developments
11.26 Apokyn
11.26.1 Apokyn Corporation Information
11.26.2 Apokyn Business Overview
11.26.3 Apokyn Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.26.4 Apokyn Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.26.5 Apokyn Recent Developments
11.27 Orion
11.27.1 Orion Corporation Information
11.27.2 Orion Business Overview
11.27.3 Orion Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.27.4 Orion Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.27.5 Orion Recent Developments
11.28 Stada Arzneimittel
11.28.1 Stada Arzneimittel Corporation Information
11.28.2 Stada Arzneimittel Business Overview
11.28.3 Stada Arzneimittel Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.28.4 Stada Arzneimittel Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.28.5 Stada Arzneimittel Recent Developments
11.29 Bausch Health
11.29.1 Bausch Health Corporation Information
11.29.2 Bausch Health Business Overview
11.29.3 Bausch Health Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.29.4 Bausch Health Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.29.5 Bausch Health Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Anti-Parkinson's Disease Drugs Industry Chain
12.2 Anti-Parkinson's Disease Drugs Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Anti-Parkinson's Disease Drugs Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Anti-Parkinson's Disease Drugs Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Anti-Parkinson's Disease Drugs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Anti-Parkinson's Disease Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Anti-Parkinson's Disease Drugs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Anti-Parkinson's Disease Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Anticholinergics
1.2.3 Dopaminergics
1.3 Market Segmentation by Application
1.3.1 Global Anti-Parkinson's Disease Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Pharmacy
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Anti-Parkinson's Disease Drugs Revenue Estimates and Forecasts 2020-2031
2.2 Global Anti-Parkinson's Disease Drugs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Anti-Parkinson's Disease Drugs Sales Estimates and Forecasts 2020-2031
2.4 Global Anti-Parkinson's Disease Drugs Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Anti-Parkinson's Disease Drugs Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Anti-Parkinson's Disease Drugs Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Anticholinergics Market Size by Manufacturers
3.5.2 Dopaminergics Market Size by Manufacturers
3.6 Global Anti-Parkinson's Disease Drugs Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Anti-Parkinson's Disease Drugs Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Anti-Parkinson's Disease Drugs Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Anti-Parkinson's Disease Drugs Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Anti-Parkinson's Disease Drugs Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Anti-Parkinson's Disease Drugs Sales and Revenue by Type (2020-2031)
6.4 North America Anti-Parkinson's Disease Drugs Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Anti-Parkinson's Disease Drugs Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Anti-Parkinson's Disease Drugs Sales and Revenue by Type (2020-2031)
7.4 Europe Anti-Parkinson's Disease Drugs Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Anti-Parkinson's Disease Drugs Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Anti-Parkinson's Disease Drugs Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Anti-Parkinson's Disease Drugs Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Anti-Parkinson's Disease Drugs Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Anti-Parkinson's Disease Drugs Sales and Revenue by Type (2020-2031)
9.4 Central and South America Anti-Parkinson's Disease Drugs Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Anti-Parkinson's Disease Drugs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Anti-Parkinson's Disease Drugs Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Anti-Parkinson's Disease Drugs Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Anti-Parkinson's Disease Drugs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Guangzhou Kanghe Pharmaceutical Co., Ltd.
11.1.1 Guangzhou Kanghe Pharmaceutical Co., Ltd. Corporation Information
11.1.2 Guangzhou Kanghe Pharmaceutical Co., Ltd. Business Overview
11.1.3 Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.1.4 Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Product in 2024
11.1.6 Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Application in 2024
11.1.7 Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Geographic Area in 2024
11.1.8 Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs SWOT Analysis
11.1.9 Guangzhou Kanghe Pharmaceutical Co., Ltd. Recent Developments
11.2 Tianjin Lisheng Pharmaceutical Co., Ltd.
11.2.1 Tianjin Lisheng Pharmaceutical Co., Ltd. Corporation Information
11.2.2 Tianjin Lisheng Pharmaceutical Co., Ltd. Business Overview
11.2.3 Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.2.4 Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Product in 2024
11.2.6 Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Application in 2024
11.2.7 Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Geographic Area in 2024
11.2.8 Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs SWOT Analysis
11.2.9 Tianjin Lisheng Pharmaceutical Co., Ltd. Recent Developments
11.3 Changzhou Kangpu Pharmaceutical Co., Ltd.
11.3.1 Changzhou Kangpu Pharmaceutical Co., Ltd. Corporation Information
11.3.2 Changzhou Kangpu Pharmaceutical Co., Ltd. Business Overview
11.3.3 Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.3.4 Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Product in 2024
11.3.6 Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Application in 2024
11.3.7 Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Geographic Area in 2024
11.3.8 Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs SWOT Analysis
11.3.9 Changzhou Kangpu Pharmaceutical Co., Ltd. Recent Developments
11.4 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd.
11.4.1 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Corporation Information
11.4.2 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Business Overview
11.4.3 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.4.4 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Product in 2024
11.4.6 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Application in 2024
11.4.7 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Geographic Area in 2024
11.4.8 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs SWOT Analysis
11.4.9 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Recent Developments
11.5 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd.
11.5.1 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Corporation Information
11.5.2 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Business Overview
11.5.3 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.5.4 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Product in 2024
11.5.6 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Application in 2024
11.5.7 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales by Geographic Area in 2024
11.5.8 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs SWOT Analysis
11.5.9 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Recent Developments
11.6 Hunan Zhongnan Pharmaceutical Co., Ltd.
11.6.1 Hunan Zhongnan Pharmaceutical Co., Ltd. Corporation Information
11.6.2 Hunan Zhongnan Pharmaceutical Co., Ltd. Business Overview
11.6.3 Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.6.4 Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Hunan Zhongnan Pharmaceutical Co., Ltd. Recent Developments
11.7 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
11.7.1 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Corporation Information
11.7.2 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Business Overview
11.7.3 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.7.4 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Recent Developments
11.8 Ningbo Dahongying Pharmaceutical Co., Ltd.
11.8.1 Ningbo Dahongying Pharmaceutical Co., Ltd. Corporation Information
11.8.2 Ningbo Dahongying Pharmaceutical Co., Ltd. Business Overview
11.8.3 Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.8.4 Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Ningbo Dahongying Pharmaceutical Co., Ltd. Recent Developments
11.9 Beijing Fuyuan Pharmaceutical Co., Ltd.
11.9.1 Beijing Fuyuan Pharmaceutical Co., Ltd. Corporation Information
11.9.2 Beijing Fuyuan Pharmaceutical Co., Ltd. Business Overview
11.9.3 Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.9.4 Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Beijing Fuyuan Pharmaceutical Co., Ltd. Recent Developments
11.10 Zhejiang Huahai Pharmaceutical Co., Ltd.
11.10.1 Zhejiang Huahai Pharmaceutical Co., Ltd. Corporation Information
11.10.2 Zhejiang Huahai Pharmaceutical Co., Ltd. Business Overview
11.10.3 Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.10.4 Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Developments
11.11 Hangzhou Guoguang Pharmaceutical Co., Ltd.
11.11.1 Hangzhou Guoguang Pharmaceutical Co., Ltd. Corporation Information
11.11.2 Hangzhou Guoguang Pharmaceutical Co., Ltd. Business Overview
11.11.3 Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.11.4 Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Hangzhou Guoguang Pharmaceutical Co., Ltd. Recent Developments
11.12 Merck
11.12.1 Merck Corporation Information
11.12.2 Merck Business Overview
11.12.3 Merck Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.12.4 Merck Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Merck Recent Developments
11.13 Akorn
11.13.1 Akorn Corporation Information
11.13.2 Akorn Business Overview
11.13.3 Akorn Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.13.4 Akorn Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.5 Akorn Recent Developments
11.14 GSK
11.14.1 GSK Corporation Information
11.14.2 GSK Business Overview
11.14.3 GSK Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.14.4 GSK Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.14.5 GSK Recent Developments
11.15 Novartis
11.15.1 Novartis Corporation Information
11.15.2 Novartis Business Overview
11.15.3 Novartis Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.15.4 Novartis Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.15.5 Novartis Recent Developments
11.16 Boehringer Ingelheim
11.16.1 Boehringer Ingelheim Corporation Information
11.16.2 Boehringer Ingelheim Business Overview
11.16.3 Boehringer Ingelheim Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.16.4 Boehringer Ingelheim Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.16.5 Boehringer Ingelheim Recent Developments
11.17 Teva Pharmaceutical
11.17.1 Teva Pharmaceutical Corporation Information
11.17.2 Teva Pharmaceutical Business Overview
11.17.3 Teva Pharmaceutical Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.17.4 Teva Pharmaceutical Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.17.5 Teva Pharmaceutical Recent Developments
11.18 Abbvie
11.18.1 Abbvie Corporation Information
11.18.2 Abbvie Business Overview
11.18.3 Abbvie Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.18.4 Abbvie Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.18.5 Abbvie Recent Developments
11.19 Kyowa Kirin
11.19.1 Kyowa Kirin Corporation Information
11.19.2 Kyowa Kirin Business Overview
11.19.3 Kyowa Kirin Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.19.4 Kyowa Kirin Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.19.5 Kyowa Kirin Recent Developments
11.20 Astellas Pharma
11.20.1 Astellas Pharma Corporation Information
11.20.2 Astellas Pharma Business Overview
11.20.3 Astellas Pharma Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.20.4 Astellas Pharma Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.20.5 Astellas Pharma Recent Developments
11.21 Desitin Arzneimittel
11.21.1 Desitin Arzneimittel Corporation Information
11.21.2 Desitin Arzneimittel Business Overview
11.21.3 Desitin Arzneimittel Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.21.4 Desitin Arzneimittel Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.21.5 Desitin Arzneimittel Recent Developments
11.22 Endo International plc
11.22.1 Endo International plc Corporation Information
11.22.2 Endo International plc Business Overview
11.22.3 Endo International plc Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.22.4 Endo International plc Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.22.5 Endo International plc Recent Developments
11.23 Roche Holding AG
11.23.1 Roche Holding AG Corporation Information
11.23.2 Roche Holding AG Business Overview
11.23.3 Roche Holding AG Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.23.4 Roche Holding AG Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.23.5 Roche Holding AG Recent Developments
11.24 Lundbeck
11.24.1 Lundbeck Corporation Information
11.24.2 Lundbeck Business Overview
11.24.3 Lundbeck Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.24.4 Lundbeck Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.24.5 Lundbeck Recent Developments
11.25 Valeant
11.25.1 Valeant Corporation Information
11.25.2 Valeant Business Overview
11.25.3 Valeant Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.25.4 Valeant Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.25.5 Valeant Recent Developments
11.26 Apokyn
11.26.1 Apokyn Corporation Information
11.26.2 Apokyn Business Overview
11.26.3 Apokyn Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.26.4 Apokyn Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.26.5 Apokyn Recent Developments
11.27 Orion
11.27.1 Orion Corporation Information
11.27.2 Orion Business Overview
11.27.3 Orion Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.27.4 Orion Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.27.5 Orion Recent Developments
11.28 Stada Arzneimittel
11.28.1 Stada Arzneimittel Corporation Information
11.28.2 Stada Arzneimittel Business Overview
11.28.3 Stada Arzneimittel Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.28.4 Stada Arzneimittel Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.28.5 Stada Arzneimittel Recent Developments
11.29 Bausch Health
11.29.1 Bausch Health Corporation Information
11.29.2 Bausch Health Business Overview
11.29.3 Bausch Health Anti-Parkinson's Disease Drugs Product Models, Descriptions and Specifications
11.29.4 Bausch Health Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.29.5 Bausch Health Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Anti-Parkinson's Disease Drugs Industry Chain
12.2 Anti-Parkinson's Disease Drugs Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Anti-Parkinson's Disease Drugs Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Anti-Parkinson's Disease Drugs Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Anti-Parkinson's Disease Drugs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Anti-Parkinson's Disease Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Anti-Parkinson's Disease Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Anti-Parkinson's Disease Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Anti-Parkinson's Disease Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Anti-Parkinson's Disease Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Anti-Parkinson's Disease Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Anti-Parkinson's Disease Drugs Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Anti-Parkinson's Disease Drugs Sales by Region (2020-2025) & (K Units)
Table 8. Global Anti-Parkinson's Disease Drugs Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Anti-Parkinson's Disease Drugs Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Anti-Parkinson's Disease Drugs Sales Share by Manufacturers (2020-2025)
Table 12. Global Anti-Parkinson's Disease Drugs Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Anti-Parkinson's Disease Drugs by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Parkinson's Disease Drugs as of 2024)
Table 16. Global Anti-Parkinson's Disease Drugs Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Anti-Parkinson's Disease Drugs Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Anti-Parkinson's Disease Drugs Manufacturing Base and Headquarters
Table 19. Global Anti-Parkinson's Disease Drugs Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Anti-Parkinson's Disease Drugs Sales by Type (2020-2025) & (K Units)
Table 23. Global Anti-Parkinson's Disease Drugs Sales by Type (2026-2031) & (K Units)
Table 24. Global Anti-Parkinson's Disease Drugs Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Anti-Parkinson's Disease Drugs Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Anti-Parkinson's Disease Drugs ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Anti-Parkinson's Disease Drugs Sales by Application (2020-2025) & (K Units)
Table 29. Global Anti-Parkinson's Disease Drugs Sales by Application (2026-2031) & (K Units)
Table 30. Anti-Parkinson's Disease Drugs High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Anti-Parkinson's Disease Drugs Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Anti-Parkinson's Disease Drugs Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Anti-Parkinson's Disease Drugs ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Anti-Parkinson's Disease Drugs Growth Accelerators and Market Barriers
Table 37. North America Anti-Parkinson's Disease Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Anti-Parkinson's Disease Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Anti-Parkinson's Disease Drugs Growth Accelerators and Market Barriers
Table 40. Europe Anti-Parkinson's Disease Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Anti-Parkinson's Disease Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Anti-Parkinson's Disease Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Anti-Parkinson's Disease Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Anti-Parkinson's Disease Drugs Growth Accelerators and Market Barriers
Table 45. Southeast Asia Anti-Parkinson's Disease Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Anti-Parkinson's Disease Drugs Investment Opportunities and Key Challenges
Table 47. Central and South America Anti-Parkinson's Disease Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Anti-Parkinson's Disease Drugs Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Anti-Parkinson's Disease Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Guangzhou Kanghe Pharmaceutical Co., Ltd. Corporation Information
Table 51. Guangzhou Kanghe Pharmaceutical Co., Ltd. Description and Major Businesses
Table 52. Guangzhou Kanghe Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 53. Guangzhou Kanghe Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Guangzhou Kanghe Pharmaceutical Co., Ltd. Sales Value Proportion by Product in 2024
Table 55. Guangzhou Kanghe Pharmaceutical Co., Ltd. Sales Value Proportion by Application in 2024
Table 56. Guangzhou Kanghe Pharmaceutical Co., Ltd. Sales Value Proportion by Geographic Area in 2024
Table 57. Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs SWOT Analysis
Table 58. Guangzhou Kanghe Pharmaceutical Co., Ltd. Recent Developments
Table 59. Tianjin Lisheng Pharmaceutical Co., Ltd. Corporation Information
Table 60. Tianjin Lisheng Pharmaceutical Co., Ltd. Description and Major Businesses
Table 61. Tianjin Lisheng Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 62. Tianjin Lisheng Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Tianjin Lisheng Pharmaceutical Co., Ltd. Sales Value Proportion by Product in 2024
Table 64. Tianjin Lisheng Pharmaceutical Co., Ltd. Sales Value Proportion by Application in 2024
Table 65. Tianjin Lisheng Pharmaceutical Co., Ltd. Sales Value Proportion by Geographic Area in 2024
Table 66. Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs SWOT Analysis
Table 67. Tianjin Lisheng Pharmaceutical Co., Ltd. Recent Developments
Table 68. Changzhou Kangpu Pharmaceutical Co., Ltd. Corporation Information
Table 69. Changzhou Kangpu Pharmaceutical Co., Ltd. Description and Major Businesses
Table 70. Changzhou Kangpu Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 71. Changzhou Kangpu Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Changzhou Kangpu Pharmaceutical Co., Ltd. Sales Value Proportion by Product in 2024
Table 73. Changzhou Kangpu Pharmaceutical Co., Ltd. Sales Value Proportion by Application in 2024
Table 74. Changzhou Kangpu Pharmaceutical Co., Ltd. Sales Value Proportion by Geographic Area in 2024
Table 75. Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs SWOT Analysis
Table 76. Changzhou Kangpu Pharmaceutical Co., Ltd. Recent Developments
Table 77. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Corporation Information
Table 78. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Description and Major Businesses
Table 79. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 80. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Sales Value Proportion by Product in 2024
Table 82. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Sales Value Proportion by Application in 2024
Table 83. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Sales Value Proportion by Geographic Area in 2024
Table 84. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs SWOT Analysis
Table 85. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Recent Developments
Table 86. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Corporation Information
Table 87. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Description and Major Businesses
Table 88. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 89. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Sales Value Proportion by Product in 2024
Table 91. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Sales Value Proportion by Application in 2024
Table 92. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Sales Value Proportion by Geographic Area in 2024
Table 93. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs SWOT Analysis
Table 94. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Recent Developments
Table 95. Hunan Zhongnan Pharmaceutical Co., Ltd. Corporation Information
Table 96. Hunan Zhongnan Pharmaceutical Co., Ltd. Description and Major Businesses
Table 97. Hunan Zhongnan Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 98. Hunan Zhongnan Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Hunan Zhongnan Pharmaceutical Co., Ltd. Recent Developments
Table 100. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Corporation Information
Table 101. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Description and Major Businesses
Table 102. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 103. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Recent Developments
Table 105. Ningbo Dahongying Pharmaceutical Co., Ltd. Corporation Information
Table 106. Ningbo Dahongying Pharmaceutical Co., Ltd. Description and Major Businesses
Table 107. Ningbo Dahongying Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 108. Ningbo Dahongying Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Ningbo Dahongying Pharmaceutical Co., Ltd. Recent Developments
Table 110. Beijing Fuyuan Pharmaceutical Co., Ltd. Corporation Information
Table 111. Beijing Fuyuan Pharmaceutical Co., Ltd. Description and Major Businesses
Table 112. Beijing Fuyuan Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 113. Beijing Fuyuan Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Beijing Fuyuan Pharmaceutical Co., Ltd. Recent Developments
Table 115. Zhejiang Huahai Pharmaceutical Co., Ltd. Corporation Information
Table 116. Zhejiang Huahai Pharmaceutical Co., Ltd. Description and Major Businesses
Table 117. Zhejiang Huahai Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 118. Zhejiang Huahai Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Developments
Table 120. Hangzhou Guoguang Pharmaceutical Co., Ltd. Corporation Information
Table 121. Hangzhou Guoguang Pharmaceutical Co., Ltd. Description and Major Businesses
Table 122. Hangzhou Guoguang Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 123. Hangzhou Guoguang Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Hangzhou Guoguang Pharmaceutical Co., Ltd. Recent Developments
Table 125. Merck Corporation Information
Table 126. Merck Description and Major Businesses
Table 127. Merck Product Models, Descriptions and Specifications
Table 128. Merck Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. Merck Recent Developments
Table 130. Akorn Corporation Information
Table 131. Akorn Description and Major Businesses
Table 132. Akorn Product Models, Descriptions and Specifications
Table 133. Akorn Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 134. Akorn Recent Developments
Table 135. GSK Corporation Information
Table 136. GSK Description and Major Businesses
Table 137. GSK Product Models, Descriptions and Specifications
Table 138. GSK Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 139. GSK Recent Developments
Table 140. Novartis Corporation Information
Table 141. Novartis Description and Major Businesses
Table 142. Novartis Product Models, Descriptions and Specifications
Table 143. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 144. Novartis Recent Developments
Table 145. Boehringer Ingelheim Corporation Information
Table 146. Boehringer Ingelheim Description and Major Businesses
Table 147. Boehringer Ingelheim Product Models, Descriptions and Specifications
Table 148. Boehringer Ingelheim Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 149. Boehringer Ingelheim Recent Developments
Table 150. Teva Pharmaceutical Corporation Information
Table 151. Teva Pharmaceutical Description and Major Businesses
Table 152. Teva Pharmaceutical Product Models, Descriptions and Specifications
Table 153. Teva Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 154. Teva Pharmaceutical Recent Developments
Table 155. Abbvie Corporation Information
Table 156. Abbvie Description and Major Businesses
Table 157. Abbvie Product Models, Descriptions and Specifications
Table 158. Abbvie Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 159. Abbvie Recent Developments
Table 160. Kyowa Kirin Corporation Information
Table 161. Kyowa Kirin Description and Major Businesses
Table 162. Kyowa Kirin Product Models, Descriptions and Specifications
Table 163. Kyowa Kirin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 164. Kyowa Kirin Recent Developments
Table 165. Astellas Pharma Corporation Information
Table 166. Astellas Pharma Description and Major Businesses
Table 167. Astellas Pharma Product Models, Descriptions and Specifications
Table 168. Astellas Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 169. Astellas Pharma Recent Developments
Table 170. Desitin Arzneimittel Corporation Information
Table 171. Desitin Arzneimittel Description and Major Businesses
Table 172. Desitin Arzneimittel Product Models, Descriptions and Specifications
Table 173. Desitin Arzneimittel Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 174. Desitin Arzneimittel Recent Developments
Table 175. Endo International plc Corporation Information
Table 176. Endo International plc Description and Major Businesses
Table 177. Endo International plc Product Models, Descriptions and Specifications
Table 178. Endo International plc Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 179. Endo International plc Recent Developments
Table 180. Roche Holding AG Corporation Information
Table 181. Roche Holding AG Description and Major Businesses
Table 182. Roche Holding AG Product Models, Descriptions and Specifications
Table 183. Roche Holding AG Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 184. Roche Holding AG Recent Developments
Table 185. Lundbeck Corporation Information
Table 186. Lundbeck Description and Major Businesses
Table 187. Lundbeck Product Models, Descriptions and Specifications
Table 188. Lundbeck Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 189. Lundbeck Recent Developments
Table 190. Valeant Corporation Information
Table 191. Valeant Description and Major Businesses
Table 192. Valeant Product Models, Descriptions and Specifications
Table 193. Valeant Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 194. Valeant Recent Developments
Table 195. Apokyn Corporation Information
Table 196. Apokyn Description and Major Businesses
Table 197. Apokyn Product Models, Descriptions and Specifications
Table 198. Apokyn Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 199. Apokyn Recent Developments
Table 200. Orion Corporation Information
Table 201. Orion Description and Major Businesses
Table 202. Orion Product Models, Descriptions and Specifications
Table 203. Orion Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 204. Orion Recent Developments
Table 205. Stada Arzneimittel Corporation Information
Table 206. Stada Arzneimittel Description and Major Businesses
Table 207. Stada Arzneimittel Product Models, Descriptions and Specifications
Table 208. Stada Arzneimittel Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 209. Stada Arzneimittel Recent Developments
Table 210. Bausch Health Corporation Information
Table 211. Bausch Health Description and Major Businesses
Table 212. Bausch Health Product Models, Descriptions and Specifications
Table 213. Bausch Health Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 214. Bausch Health Recent Developments
Table 215. Key Raw Materials Distribution
Table 216. Raw Materials Key Suppliers
Table 217. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 218. Milestones in Production Technology Evolution
Table 219. Distributors List
Table 220. Market Trends and Market Evolution
Table 221. Market Drivers and Opportunities
Table 222. Market Challenges, Risks, and Restraints
Table 223. Research Programs/Design for This Report
Table 224. Key Data Information from Secondary Sources
Table 225. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-Parkinson's Disease Drugs Product Picture
Figure 2. Global Anti-Parkinson's Disease Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Anticholinergics Product Picture
Figure 4. Dopaminergics Product Picture
Figure 5. Global Anti-Parkinson's Disease Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Hospital
Figure 7. Clinic
Figure 8. Pharmacy
Figure 9. Other
Figure 10. Anti-Parkinson's Disease Drugs Report Years Considered
Figure 11. Global Anti-Parkinson's Disease Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 13. Global Anti-Parkinson's Disease Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Region (2020-2031)
Figure 15. Global Anti-Parkinson's Disease Drugs Sales (2020-2031) & (K Units)
Figure 16. Global Anti-Parkinson's Disease Drugs Sales (CAGR) by Region (2020-2031) (K Units)
Figure 17. Global Anti-Parkinson's Disease Drugs Sales Market Share by Region (2020-2031)
Figure 18. Top 5 and Top 10 Manufacturers Anti-Parkinson's Disease Drugs Sales Volume Market Share in 2024
Figure 19. Global Anti-Parkinson's Disease Drugs Revenue Market Share Ranking (2024)
Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 21. Anticholinergics Revenue Market Share by Manufacturer in 2024
Figure 22. Dopaminergics Revenue Market Share by Manufacturer in 2024
Figure 23. Global Anti-Parkinson's Disease Drugs Sales Market Share by Type (2020-2031)
Figure 24. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Type (2020-2031)
Figure 25. Global Anti-Parkinson's Disease Drugs Sales Market Share by Application (2020-2031)
Figure 26. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Application (2020-2031)
Figure 27. North America Anti-Parkinson's Disease Drugs Sales YoY (2020-2031) & (K Units)
Figure 28. North America Anti-Parkinson's Disease Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 29. North America Top 5 Manufacturers Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) in 2024
Figure 30. North America Anti-Parkinson's Disease Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 31. North America Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 32. North America Anti-Parkinson's Disease Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 33. North America Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 34. US Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 35. Canada Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 36. Mexico Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 37. Europe Anti-Parkinson's Disease Drugs Sales YoY (2020-2031) & (K Units)
Figure 38. Europe Anti-Parkinson's Disease Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 39. Europe Top 5 Manufacturers Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) in 2024
Figure 40. Europe Anti-Parkinson's Disease Drugs Sales Volume (K Units) by Type (2020-2031)
Figure 41. Europe Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 42. Europe Anti-Parkinson's Disease Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 43. Europe Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 44. Germany Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 45. France Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 46. U.K. Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 47. Italy Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 48. Russia Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 49. Asia-Pacific Anti-Parkinson's Disease Drugs Sales YoY (2020-2031) & (K Units)
Figure 50. Asia-Pacific Anti-Parkinson's Disease Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 51. Asia-Pacific Top 8 Manufacturers Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) in 2024
Figure 52. Asia-Pacific Anti-Parkinson's Disease Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 53. Asia-Pacific Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 54. Asia-Pacific Anti-Parkinson's Disease Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 55. Asia-Pacific Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 56. Indonesia Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 57. Japan Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 58. South Korea Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 59. China Taiwan Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 60. India Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 61. Central and South America Anti-Parkinson's Disease Drugs Sales YoY (2020-2031) & (K Units)
Figure 62. Central and South America Anti-Parkinson's Disease Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 63. Central and South America Top 5 Manufacturers Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) in 2024
Figure 64. Central and South America Anti-Parkinson's Disease Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 65. Central and South America Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 66. Central and South America Anti-Parkinson's Disease Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 67. Central and South America Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 68. Brazil Anti-Parkinson's Disease Drugs Revenue (2020-2025) & (US$ Million)
Figure 69. Argentina Anti-Parkinson's Disease Drugs Revenue (2020-2025) & (US$ Million)
Figure 70. Middle East, and Africa Anti-Parkinson's Disease Drugs Sales YoY (2020-2031) & (K Units)
Figure 71. Middle East and Africa Anti-Parkinson's Disease Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 72. Middle East and Africa Top 5 Manufacturers Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) in 2024
Figure 73. Middle East and Africa Anti-Parkinson's Disease Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 74. South America Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 75. Middle East and Africa Anti-Parkinson's Disease Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 76. Middle East and Africa Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 77. GCC Countries Anti-Parkinson's Disease Drugs Revenue (2020-2025) & (US$ Million)
Figure 78. Turkey Anti-Parkinson's Disease Drugs Revenue (2020-2025) & (US$ Million)
Figure 79. Egypt Anti-Parkinson's Disease Drugs Revenue (2020-2025) & (US$ Million)
Figure 80. South Africa Anti-Parkinson's Disease Drugs Revenue (2020-2025) & (US$ Million)
Figure 81. Anti-Parkinson's Disease Drugs Industry Chain Mapping
Figure 82. Regional Anti-Parkinson's Disease Drugs Manufacturing Base Distribution (%)
Figure 83. Global Anti-Parkinson's Disease Drugs Production Market Share by Region (2020-2031)
Figure 84. Anti-Parkinson's Disease Drugs Production Process
Figure 85. Regional Anti-Parkinson's Disease Drugs Production Cost Structure
Figure 86. Channels of Distribution (Direct Vs Distribution)
Figure 87. Bottom-up and Top-down Approaches for This Report
Figure 88. Data Triangulation
Figure 89. Key Executives Interviewed
Table 1. Global Anti-Parkinson's Disease Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Anti-Parkinson's Disease Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Anti-Parkinson's Disease Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Anti-Parkinson's Disease Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Anti-Parkinson's Disease Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Anti-Parkinson's Disease Drugs Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Anti-Parkinson's Disease Drugs Sales by Region (2020-2025) & (K Units)
Table 8. Global Anti-Parkinson's Disease Drugs Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Anti-Parkinson's Disease Drugs Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Anti-Parkinson's Disease Drugs Sales Share by Manufacturers (2020-2025)
Table 12. Global Anti-Parkinson's Disease Drugs Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Anti-Parkinson's Disease Drugs by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Parkinson's Disease Drugs as of 2024)
Table 16. Global Anti-Parkinson's Disease Drugs Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Anti-Parkinson's Disease Drugs Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Anti-Parkinson's Disease Drugs Manufacturing Base and Headquarters
Table 19. Global Anti-Parkinson's Disease Drugs Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Anti-Parkinson's Disease Drugs Sales by Type (2020-2025) & (K Units)
Table 23. Global Anti-Parkinson's Disease Drugs Sales by Type (2026-2031) & (K Units)
Table 24. Global Anti-Parkinson's Disease Drugs Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Anti-Parkinson's Disease Drugs Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Anti-Parkinson's Disease Drugs ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Anti-Parkinson's Disease Drugs Sales by Application (2020-2025) & (K Units)
Table 29. Global Anti-Parkinson's Disease Drugs Sales by Application (2026-2031) & (K Units)
Table 30. Anti-Parkinson's Disease Drugs High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Anti-Parkinson's Disease Drugs Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Anti-Parkinson's Disease Drugs Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Anti-Parkinson's Disease Drugs ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Anti-Parkinson's Disease Drugs Growth Accelerators and Market Barriers
Table 37. North America Anti-Parkinson's Disease Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Anti-Parkinson's Disease Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Anti-Parkinson's Disease Drugs Growth Accelerators and Market Barriers
Table 40. Europe Anti-Parkinson's Disease Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Anti-Parkinson's Disease Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Anti-Parkinson's Disease Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Anti-Parkinson's Disease Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Anti-Parkinson's Disease Drugs Growth Accelerators and Market Barriers
Table 45. Southeast Asia Anti-Parkinson's Disease Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Anti-Parkinson's Disease Drugs Investment Opportunities and Key Challenges
Table 47. Central and South America Anti-Parkinson's Disease Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Anti-Parkinson's Disease Drugs Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Anti-Parkinson's Disease Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Guangzhou Kanghe Pharmaceutical Co., Ltd. Corporation Information
Table 51. Guangzhou Kanghe Pharmaceutical Co., Ltd. Description and Major Businesses
Table 52. Guangzhou Kanghe Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 53. Guangzhou Kanghe Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Guangzhou Kanghe Pharmaceutical Co., Ltd. Sales Value Proportion by Product in 2024
Table 55. Guangzhou Kanghe Pharmaceutical Co., Ltd. Sales Value Proportion by Application in 2024
Table 56. Guangzhou Kanghe Pharmaceutical Co., Ltd. Sales Value Proportion by Geographic Area in 2024
Table 57. Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs SWOT Analysis
Table 58. Guangzhou Kanghe Pharmaceutical Co., Ltd. Recent Developments
Table 59. Tianjin Lisheng Pharmaceutical Co., Ltd. Corporation Information
Table 60. Tianjin Lisheng Pharmaceutical Co., Ltd. Description and Major Businesses
Table 61. Tianjin Lisheng Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 62. Tianjin Lisheng Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Tianjin Lisheng Pharmaceutical Co., Ltd. Sales Value Proportion by Product in 2024
Table 64. Tianjin Lisheng Pharmaceutical Co., Ltd. Sales Value Proportion by Application in 2024
Table 65. Tianjin Lisheng Pharmaceutical Co., Ltd. Sales Value Proportion by Geographic Area in 2024
Table 66. Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs SWOT Analysis
Table 67. Tianjin Lisheng Pharmaceutical Co., Ltd. Recent Developments
Table 68. Changzhou Kangpu Pharmaceutical Co., Ltd. Corporation Information
Table 69. Changzhou Kangpu Pharmaceutical Co., Ltd. Description and Major Businesses
Table 70. Changzhou Kangpu Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 71. Changzhou Kangpu Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Changzhou Kangpu Pharmaceutical Co., Ltd. Sales Value Proportion by Product in 2024
Table 73. Changzhou Kangpu Pharmaceutical Co., Ltd. Sales Value Proportion by Application in 2024
Table 74. Changzhou Kangpu Pharmaceutical Co., Ltd. Sales Value Proportion by Geographic Area in 2024
Table 75. Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs SWOT Analysis
Table 76. Changzhou Kangpu Pharmaceutical Co., Ltd. Recent Developments
Table 77. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Corporation Information
Table 78. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Description and Major Businesses
Table 79. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 80. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Sales Value Proportion by Product in 2024
Table 82. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Sales Value Proportion by Application in 2024
Table 83. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Sales Value Proportion by Geographic Area in 2024
Table 84. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs SWOT Analysis
Table 85. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Recent Developments
Table 86. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Corporation Information
Table 87. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Description and Major Businesses
Table 88. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 89. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Sales Value Proportion by Product in 2024
Table 91. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Sales Value Proportion by Application in 2024
Table 92. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Sales Value Proportion by Geographic Area in 2024
Table 93. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs SWOT Analysis
Table 94. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Recent Developments
Table 95. Hunan Zhongnan Pharmaceutical Co., Ltd. Corporation Information
Table 96. Hunan Zhongnan Pharmaceutical Co., Ltd. Description and Major Businesses
Table 97. Hunan Zhongnan Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 98. Hunan Zhongnan Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Hunan Zhongnan Pharmaceutical Co., Ltd. Recent Developments
Table 100. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Corporation Information
Table 101. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Description and Major Businesses
Table 102. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 103. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Recent Developments
Table 105. Ningbo Dahongying Pharmaceutical Co., Ltd. Corporation Information
Table 106. Ningbo Dahongying Pharmaceutical Co., Ltd. Description and Major Businesses
Table 107. Ningbo Dahongying Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 108. Ningbo Dahongying Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Ningbo Dahongying Pharmaceutical Co., Ltd. Recent Developments
Table 110. Beijing Fuyuan Pharmaceutical Co., Ltd. Corporation Information
Table 111. Beijing Fuyuan Pharmaceutical Co., Ltd. Description and Major Businesses
Table 112. Beijing Fuyuan Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 113. Beijing Fuyuan Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Beijing Fuyuan Pharmaceutical Co., Ltd. Recent Developments
Table 115. Zhejiang Huahai Pharmaceutical Co., Ltd. Corporation Information
Table 116. Zhejiang Huahai Pharmaceutical Co., Ltd. Description and Major Businesses
Table 117. Zhejiang Huahai Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 118. Zhejiang Huahai Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Developments
Table 120. Hangzhou Guoguang Pharmaceutical Co., Ltd. Corporation Information
Table 121. Hangzhou Guoguang Pharmaceutical Co., Ltd. Description and Major Businesses
Table 122. Hangzhou Guoguang Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 123. Hangzhou Guoguang Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Hangzhou Guoguang Pharmaceutical Co., Ltd. Recent Developments
Table 125. Merck Corporation Information
Table 126. Merck Description and Major Businesses
Table 127. Merck Product Models, Descriptions and Specifications
Table 128. Merck Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. Merck Recent Developments
Table 130. Akorn Corporation Information
Table 131. Akorn Description and Major Businesses
Table 132. Akorn Product Models, Descriptions and Specifications
Table 133. Akorn Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 134. Akorn Recent Developments
Table 135. GSK Corporation Information
Table 136. GSK Description and Major Businesses
Table 137. GSK Product Models, Descriptions and Specifications
Table 138. GSK Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 139. GSK Recent Developments
Table 140. Novartis Corporation Information
Table 141. Novartis Description and Major Businesses
Table 142. Novartis Product Models, Descriptions and Specifications
Table 143. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 144. Novartis Recent Developments
Table 145. Boehringer Ingelheim Corporation Information
Table 146. Boehringer Ingelheim Description and Major Businesses
Table 147. Boehringer Ingelheim Product Models, Descriptions and Specifications
Table 148. Boehringer Ingelheim Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 149. Boehringer Ingelheim Recent Developments
Table 150. Teva Pharmaceutical Corporation Information
Table 151. Teva Pharmaceutical Description and Major Businesses
Table 152. Teva Pharmaceutical Product Models, Descriptions and Specifications
Table 153. Teva Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 154. Teva Pharmaceutical Recent Developments
Table 155. Abbvie Corporation Information
Table 156. Abbvie Description and Major Businesses
Table 157. Abbvie Product Models, Descriptions and Specifications
Table 158. Abbvie Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 159. Abbvie Recent Developments
Table 160. Kyowa Kirin Corporation Information
Table 161. Kyowa Kirin Description and Major Businesses
Table 162. Kyowa Kirin Product Models, Descriptions and Specifications
Table 163. Kyowa Kirin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 164. Kyowa Kirin Recent Developments
Table 165. Astellas Pharma Corporation Information
Table 166. Astellas Pharma Description and Major Businesses
Table 167. Astellas Pharma Product Models, Descriptions and Specifications
Table 168. Astellas Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 169. Astellas Pharma Recent Developments
Table 170. Desitin Arzneimittel Corporation Information
Table 171. Desitin Arzneimittel Description and Major Businesses
Table 172. Desitin Arzneimittel Product Models, Descriptions and Specifications
Table 173. Desitin Arzneimittel Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 174. Desitin Arzneimittel Recent Developments
Table 175. Endo International plc Corporation Information
Table 176. Endo International plc Description and Major Businesses
Table 177. Endo International plc Product Models, Descriptions and Specifications
Table 178. Endo International plc Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 179. Endo International plc Recent Developments
Table 180. Roche Holding AG Corporation Information
Table 181. Roche Holding AG Description and Major Businesses
Table 182. Roche Holding AG Product Models, Descriptions and Specifications
Table 183. Roche Holding AG Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 184. Roche Holding AG Recent Developments
Table 185. Lundbeck Corporation Information
Table 186. Lundbeck Description and Major Businesses
Table 187. Lundbeck Product Models, Descriptions and Specifications
Table 188. Lundbeck Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 189. Lundbeck Recent Developments
Table 190. Valeant Corporation Information
Table 191. Valeant Description and Major Businesses
Table 192. Valeant Product Models, Descriptions and Specifications
Table 193. Valeant Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 194. Valeant Recent Developments
Table 195. Apokyn Corporation Information
Table 196. Apokyn Description and Major Businesses
Table 197. Apokyn Product Models, Descriptions and Specifications
Table 198. Apokyn Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 199. Apokyn Recent Developments
Table 200. Orion Corporation Information
Table 201. Orion Description and Major Businesses
Table 202. Orion Product Models, Descriptions and Specifications
Table 203. Orion Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 204. Orion Recent Developments
Table 205. Stada Arzneimittel Corporation Information
Table 206. Stada Arzneimittel Description and Major Businesses
Table 207. Stada Arzneimittel Product Models, Descriptions and Specifications
Table 208. Stada Arzneimittel Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 209. Stada Arzneimittel Recent Developments
Table 210. Bausch Health Corporation Information
Table 211. Bausch Health Description and Major Businesses
Table 212. Bausch Health Product Models, Descriptions and Specifications
Table 213. Bausch Health Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 214. Bausch Health Recent Developments
Table 215. Key Raw Materials Distribution
Table 216. Raw Materials Key Suppliers
Table 217. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 218. Milestones in Production Technology Evolution
Table 219. Distributors List
Table 220. Market Trends and Market Evolution
Table 221. Market Drivers and Opportunities
Table 222. Market Challenges, Risks, and Restraints
Table 223. Research Programs/Design for This Report
Table 224. Key Data Information from Secondary Sources
Table 225. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-Parkinson's Disease Drugs Product Picture
Figure 2. Global Anti-Parkinson's Disease Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Anticholinergics Product Picture
Figure 4. Dopaminergics Product Picture
Figure 5. Global Anti-Parkinson's Disease Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Hospital
Figure 7. Clinic
Figure 8. Pharmacy
Figure 9. Other
Figure 10. Anti-Parkinson's Disease Drugs Report Years Considered
Figure 11. Global Anti-Parkinson's Disease Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 13. Global Anti-Parkinson's Disease Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Region (2020-2031)
Figure 15. Global Anti-Parkinson's Disease Drugs Sales (2020-2031) & (K Units)
Figure 16. Global Anti-Parkinson's Disease Drugs Sales (CAGR) by Region (2020-2031) (K Units)
Figure 17. Global Anti-Parkinson's Disease Drugs Sales Market Share by Region (2020-2031)
Figure 18. Top 5 and Top 10 Manufacturers Anti-Parkinson's Disease Drugs Sales Volume Market Share in 2024
Figure 19. Global Anti-Parkinson's Disease Drugs Revenue Market Share Ranking (2024)
Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 21. Anticholinergics Revenue Market Share by Manufacturer in 2024
Figure 22. Dopaminergics Revenue Market Share by Manufacturer in 2024
Figure 23. Global Anti-Parkinson's Disease Drugs Sales Market Share by Type (2020-2031)
Figure 24. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Type (2020-2031)
Figure 25. Global Anti-Parkinson's Disease Drugs Sales Market Share by Application (2020-2031)
Figure 26. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Application (2020-2031)
Figure 27. North America Anti-Parkinson's Disease Drugs Sales YoY (2020-2031) & (K Units)
Figure 28. North America Anti-Parkinson's Disease Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 29. North America Top 5 Manufacturers Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) in 2024
Figure 30. North America Anti-Parkinson's Disease Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 31. North America Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 32. North America Anti-Parkinson's Disease Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 33. North America Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 34. US Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 35. Canada Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 36. Mexico Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 37. Europe Anti-Parkinson's Disease Drugs Sales YoY (2020-2031) & (K Units)
Figure 38. Europe Anti-Parkinson's Disease Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 39. Europe Top 5 Manufacturers Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) in 2024
Figure 40. Europe Anti-Parkinson's Disease Drugs Sales Volume (K Units) by Type (2020-2031)
Figure 41. Europe Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 42. Europe Anti-Parkinson's Disease Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 43. Europe Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 44. Germany Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 45. France Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 46. U.K. Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 47. Italy Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 48. Russia Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 49. Asia-Pacific Anti-Parkinson's Disease Drugs Sales YoY (2020-2031) & (K Units)
Figure 50. Asia-Pacific Anti-Parkinson's Disease Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 51. Asia-Pacific Top 8 Manufacturers Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) in 2024
Figure 52. Asia-Pacific Anti-Parkinson's Disease Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 53. Asia-Pacific Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 54. Asia-Pacific Anti-Parkinson's Disease Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 55. Asia-Pacific Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 56. Indonesia Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 57. Japan Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 58. South Korea Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 59. China Taiwan Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 60. India Anti-Parkinson's Disease Drugs Revenue (2020-2031) & (US$ Million)
Figure 61. Central and South America Anti-Parkinson's Disease Drugs Sales YoY (2020-2031) & (K Units)
Figure 62. Central and South America Anti-Parkinson's Disease Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 63. Central and South America Top 5 Manufacturers Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) in 2024
Figure 64. Central and South America Anti-Parkinson's Disease Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 65. Central and South America Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 66. Central and South America Anti-Parkinson's Disease Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 67. Central and South America Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 68. Brazil Anti-Parkinson's Disease Drugs Revenue (2020-2025) & (US$ Million)
Figure 69. Argentina Anti-Parkinson's Disease Drugs Revenue (2020-2025) & (US$ Million)
Figure 70. Middle East, and Africa Anti-Parkinson's Disease Drugs Sales YoY (2020-2031) & (K Units)
Figure 71. Middle East and Africa Anti-Parkinson's Disease Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 72. Middle East and Africa Top 5 Manufacturers Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) in 2024
Figure 73. Middle East and Africa Anti-Parkinson's Disease Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 74. South America Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 75. Middle East and Africa Anti-Parkinson's Disease Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 76. Middle East and Africa Anti-Parkinson's Disease Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 77. GCC Countries Anti-Parkinson's Disease Drugs Revenue (2020-2025) & (US$ Million)
Figure 78. Turkey Anti-Parkinson's Disease Drugs Revenue (2020-2025) & (US$ Million)
Figure 79. Egypt Anti-Parkinson's Disease Drugs Revenue (2020-2025) & (US$ Million)
Figure 80. South Africa Anti-Parkinson's Disease Drugs Revenue (2020-2025) & (US$ Million)
Figure 81. Anti-Parkinson's Disease Drugs Industry Chain Mapping
Figure 82. Regional Anti-Parkinson's Disease Drugs Manufacturing Base Distribution (%)
Figure 83. Global Anti-Parkinson's Disease Drugs Production Market Share by Region (2020-2031)
Figure 84. Anti-Parkinson's Disease Drugs Production Process
Figure 85. Regional Anti-Parkinson's Disease Drugs Production Cost Structure
Figure 86. Channels of Distribution (Direct Vs Distribution)
Figure 87. Bottom-up and Top-down Approaches for This Report
Figure 88. Data Triangulation
Figure 89. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Oral Antianginal Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Polyester BCF Yarns Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Glass Mat Reinforced Thermoplastics (GMT) for Automotive Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232